Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 5/20 | 0.71 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.71 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2439949 | 0.83 | AVPR2 (1.00) | AVPR2AVPR1A | |
| SCHEMBL2444074 | 0.80 | AVPR2 (0.69) | AVPR2AVPR1ANR1H2NR1H3 | |
| SCHEMBL2435304 | 0.76 | AVPR2 (0.64) | AVPR2AVPR1ANPBWR1NR1H2NR1H3 | |
| SCHEMBL8233525 | 0.76 | AVPR2 (0.51) | AVPR2AVPR1ANPBWR1TP53LMNA | |
| SCHEMBL6927916 | 0.74 | AVPR2 (0.48) | AVPR2AVPR1ATP53KMT2APDE1B | |
| SCHEMBL18808535 | 0.68 | AVPR2 (0.55) | AVPR2AVPR1ANPBWR1TP53MEN1 | |
| SCHEMBL4499194 | 0.66 | AVPR2 (0.55) | AVPR2AVPR1ANPBWR1TP53MEN1 | |
| SCHEMBL8237067 | 0.63 | TSHR (0.54) | AVPR2AVPR1ATP53MEN1KMT2A | |
| SCHEMBL8227401 | 0.63 | AVPR2 (0.47) | AVPR2AVPR1ALMNAHTTSMN1; SMN2 | |
| SCHEMBL4499208 | 0.62 | AVPR2 (0.56) | AVPR2AVPR1ANPBWR1TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9687476-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-27 | — | — | US | disclosed |
| US-9687476-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-27 | — | — | US | disclosed |
| US-9687476-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-2539326-B1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER IP GMBH (DE) | 2017-05-03 | — | — | EP | disclosed |
| EP-2539326-B1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER IP GMBH (DE) | 2017-05-03 | — | — | EP | disclosed |
| US-20160051518-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-25 | — | — | US | disclosed |
| US-9187466-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187466-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187466-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-20130190330-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20130190330-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20130190330-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| EP-2539326-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011104322-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011104322-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190330-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | NAT1, AADAC, TNNI3 | AVPR2 3835/4885AVPR1A 3944/4885NPBWR1 4585/4885 |
| US-20160051518-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | NAT1, AADAC, TNNI3 | AVPR2 3835/4885AVPR1A 3944/4885NPBWR1 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.